‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use - Summary - MDSpire
Commentary & Perspectives

‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use

Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer...

  • By

  • Caroline Helwick

  • May 6, 2026

  • 8 min

Share

Circulating tumor DNA (ctDNA) testing holds promise for guiding treatment in early breast cancer, but current trials lack evidence that it improves patient outcomes, highlights Dr. Heather A. Parsons at the Miami Breast Cancer Conference. While past studies show a strong association between ctDNA presence and distant recurrence, no definitive trials confirm its utility in altering treatment decisions. Dr. Parsons urges caution and emphasizes that prognostic associations do not equate to established clinical benefits, foreseeing ctDNA's pivotal role as research progresses.

Original Source(s)

‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use

  • by Caroline Helwick

  • May 6, 2026

Related Content

One Pathway for Esophageal Cancer?

Molecular profiling reveals precursor signals in BE-negative esophageal cancer

  • May 7, 2026

  • 2 min
Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study

In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...

Experimental Daraxonrasib Shows Promise in Advanced Pancreatic Cancer

Metastatic pancreatic ductal adenocarcinoma remains one of the most challenging malignancies to treat in clinical oncology.

  • by

  • May 6, 2026

  • 5 min